About this Research Topic
Background: The recruitment of leukocytes into the tissue is a fundamental component of inflammation. The leukocytes’ migration cascade has several processes; (i) tethering and rolling on the vessel wall, (ii) firm arrest on the endothelium, (iii) crawling in all directions on the vessel, (iv) transendothelial migration and entry into tissue. This process of leukocytes recruitment across blood vessels into tissue is tightly controlled by the chemoattractant system.
Chemoattractant, such as chemokines, complements and lipid mediators, and their G protein-coupled seven transmembrane spanning receptors control the migratory patterns, position and cellular interactions of leukocytes that express multiple chemoattractant receptors. The levels of chemoattractants and its receptors are increased in the blood and within inflamed tissue of patients with autoimmune diseases, including rheumatoid arthritis (RA), vasculitis, systemic lupus erythematosus (SLE), myositis, multiple sclerosis (MS) and inflammatory bowel diseases (IBD) as well as infection with human immunodeficiency virus (HIV) and human simplex virus (HSV). The chemoattractant system controls the recruitment of leukocytes from the circulation into the extravascular space, which are central to the pathogenesis of those inflammatory diseases. Therefore, the chemoattractant system could be a new promising target for those inflammatory diseases.
Goal: Even though numerous chemoattractant systems and their receptors are involved in the recruitment of leukocytes into inflamed organs during inflammation, how multiple chemoattractant systems collaborate to coordinate the recruitment of leukocytes into the inflamed tissue is still unknown. Although the blockade of various chemoattractant systems has also shown promising results in animal models of inflammatory diseases, whether blocking the chemoattractant system has clinical benefits in human inflammatory diseases remains unclear. Hence, the role of the chemoattractant system during inflammation still requires further studies.
Scope: The aim of this Research Topic is to define the functional role for chemoattractants during inflammation, including autoimmune diseases such like RA, vasculitis, SLE, myositis, MS and IBD as well as infections with HIV, HSV and bacteria. In addition, manuscripts that evaluate the therapeutic application of the chemoattractant system and clinical trials are welcome.
Detail for Authors: We encourage investigators to submit to this Research Topic from Original research to Review Articles about the mechanism, biomarkers, drugs and clinical trials of the chemoattractant system in inflammatory diseases.
Chemoattractant, such as chemokines, complements and lipid mediators, and their G protein-coupled seven transmembrane spanning receptors control the migratory patterns, position and cellular interactions of leukocytes that express multiple chemoattractant receptors. The levels of chemoattractants and its receptors are increased in the blood and within inflamed tissue of patients with autoimmune diseases, including rheumatoid arthritis (RA), vasculitis, systemic lupus erythematosus (SLE), myositis, multiple sclerosis (MS) and inflammatory bowel diseases (IBD) as well as infection with human immunodeficiency virus (HIV) and human simplex virus (HSV). The chemoattractant system controls the recruitment of leukocytes from the circulation into the extravascular space, which are central to the pathogenesis of those inflammatory diseases. Therefore, the chemoattractant system could be a new promising target for those inflammatory diseases.
Goal: Even though numerous chemoattractant systems and their receptors are involved in the recruitment of leukocytes into inflamed organs during inflammation, how multiple chemoattractant systems collaborate to coordinate the recruitment of leukocytes into the inflamed tissue is still unknown. Although the blockade of various chemoattractant systems has also shown promising results in animal models of inflammatory diseases, whether blocking the chemoattractant system has clinical benefits in human inflammatory diseases remains unclear. Hence, the role of the chemoattractant system during inflammation still requires further studies.
Scope: The aim of this Research Topic is to define the functional role for chemoattractants during inflammation, including autoimmune diseases such like RA, vasculitis, SLE, myositis, MS and IBD as well as infections with HIV, HSV and bacteria. In addition, manuscripts that evaluate the therapeutic application of the chemoattractant system and clinical trials are welcome.
Detail for Authors: We encourage investigators to submit to this Research Topic from Original research to Review Articles about the mechanism, biomarkers, drugs and clinical trials of the chemoattractant system in inflammatory diseases.
Keywords: Chemokine, complement, lipid mediator, immunology, inflammation
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
